Source The COVID-19 pandemic has had a positive effect on the market for Glucagon-like Peptide-1 (GLP-1) Agonists as people with diabetes and high blood sugar levels are more likely to become seriously ill or die if they catch COVID-19
NAD+ IV therapy has gone from biohacking niche to mainstream wellness in just a few years
But there are many other classes of medications that are being explored
Saunders takes a similarly cautious strategy with her patients: When our patients are off medication for an extended period, we generally recommend starting back at the lowest dose and titrating up gradually. The more doses a person has missed, the more likely they are to have difficulty tolerating the medication when they restart it, and the more likely they are to have gastrointestinal side effects, Low Wang says
Preferences vary by patient, Mir Ali, MD, a bariatric surgeon and the medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA, told Healthine in an earlier interview